Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishigaki, Y.
Right arrow Articles by Oka, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishigaki, Y.
Right arrow Articles by Oka, Y.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:322-332, 2005
© 2005 by the American Diabetes Association, Inc.

Dissipating Excess Energy Stored in the Liver Is a Potential Treatment Strategy for Diabetes Associated With Obesity

Yasushi Ishigaki1, Hideki Katagiri2, Tetsuya Yamada1, Takehide Ogihara2, Junta Imai1,2, Kenji Uno1,2, Yutaka Hasegawa1,2, Junhong Gao1,2, Hisamitsu Ishihara1, Tooru Shimosegawa3, Hideyuki Sakoda4, Tomoichiro Asano4, and Yoshitomo Oka1

1 Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan
2 Division of Advanced Therapeutics for Metabolic Diseases, Center for Translational and Advanced Animal Research, Tohoku University Graduate School of Medicine, Sendai, Japan
3 Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan
4 Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan

For examining whether dissipating excess energy in the liver is a possible therapeutic approach to high-fat diet–induced metabolic disorders, uncoupling protein-1 (UCP1) was expressed in murine liver using adenoviral vectors in mice with high-fat diet–induced diabetes and obesity, and in standard diet–fed lean mice. Once diabetes with obesity developed, hepatic UCP1 expression increased energy expenditure, decreased body weight, and reduced fat in the liver and adipose tissues, resulting in markedly improved insulin resistance and, thus, diabetes and dyslipidemia. Decreased expressions of enzymes for lipid synthesis and glucose production and activation of AMP-activated kinase in the liver seem to contribute to these improvements. Hepatic UCP1 expression also reversed high-fat diet–induced hyperphagia and hypothalamic leptin resistance, as well as insulin resistance in muscle. In contrast, intriguingly, in standard diet–fed lean mice, hepatic UCP1 expression did not significantly affect energy expenditure or hepatic ATP contents. Furthermore, no alterations in blood glucose levels, body weight, or adiposity were observed. These findings suggest that ectopic UCP1 in the liver dissipates surplus energy without affecting required energy and exerts minimal metabolic effects in lean mice. Thus, enhanced UCP expression in the liver is a new potential therapeutic target for the metabolic syndrome.

Address correspondence and reprint requests to Hideki Katagiri, MD, PhD, Division of Advanced and Therapeutics for Metabolic Diseases, Center for TranslationalAdvanced Animal Research, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. E-mail: katagiri-tky{at}umin.ac.jp

Abbreviations: ACC1, acetyl-CoA carboxylase 1; AMPK, AMP-activated protein kinase; CPT1, carnitine palmitoyltransferase 1; IRS1, insulin receptor substrate 1; PPAR, peroxisome proliferator–activated receptor; SREBP, sterol regulatory element binding protein; TNF-{alpha}, tumor necrosis factor-{alpha}; UCP, uncoupling protein


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. S. Choi, D. B. Savage, A. Kulkarni, X. X. Yu, Z.-X. Liu, K. Morino, S. Kim, A. Distefano, V. T. Samuel, S. Neschen, et al.
Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance
J. Biol. Chem., August 3, 2007; 282(31): 22678 - 22688.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
H. Katagiri, T. Yamada, and Y. Oka
Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals
Circ. Res., July 6, 2007; 101(1): 27 - 39.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Gao, H. Katagiri, Y. Ishigaki, T. Yamada, T. Ogihara, J. Imai, K. Uno, Y. Hasegawa, M. Kanzaki, T. T. Yamamoto, et al.
Involvement of Apolipoprotein E in Excess Fat Accumulation and Insulin Resistance
Diabetes, January 1, 2007; 56(1): 24 - 33.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Penza, C. Montani, A. Romani, P. Vignolini, B. Pampaloni, A. Tanini, M. L. Brandi, P. Alonso-Magdalena, A. Nadal, L. Ottobrini, et al.
Genistein Affects Adipose Tissue Deposition in a Dose-Dependent and Gender-Specific Manner
Endocrinology, December 1, 2006; 147(12): 5740 - 5751.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
K. Uno, H. Katagiri, T. Yamada, Y. Ishigaki, T. Ogihara, J. Imai, Y. Hasegawa, J. Gao, K. Kaneko, H. Iwasaki, et al.
Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity.
Science, June 16, 2006; 312(5780): 1656 - 1659.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.